Based on these results, in 2021, the FDA-approved, nivolumab plus fluoropyrimidine- and platinum-based chemotherapy as a first-line therapy for HER2-negative advanced or metastatic G/GEJ and esophageal adenocarcinoma [2]. This evidence concerns the gene ERBB2 and esophageal adenocarcinoma.